Microbix Biosystems reports Q4 revenue C$3.74M vs. C$6.29M last year

The company said, “Microbix added to both its capabilities and capacity across 2025, improving manufacturing processes, adding new products, and expanding its base of ongoing client relationships. However, setbacks relating to two clients overshadowed our broader progress – Resulting in reduced revenues through the second-half of 2025. Microbix is now hard at work adding new products, programs, and clients to rebuild revenues beyond its quarterly breakeven point…Microbix is aggressively pursuing new client programs and new clients, while continuing to add to its portfolio of products and services. It thereby intends to continue driving sales growth across all of its business lines, while also improving percentage gross margins and working to deliver bottom-line results. Microbix’s goal is to create meaningful and sustained shareholder value within both its diagnostics-oriented business and its fully-funded Kinlytic urokinase drug program.”